Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) launched Quest AI Companion on March 2, 2026, an AI chat feature in MyQuest that analyzes up to five years of Quest lab data to explain results, highlight trends, and help users prepare questions for clinicians.
Powered by Google’s Gemini models via a strategic Google Cloud collaboration (established March 2025), the tool operates within the HIPAA-compliant MyQuest platform and is available to adult users; it is educational and not a substitute for professional medical advice.
Quest Diagnostics (NYSE: DGX) named Benjamin Beauvalot senior vice president, chief strategy and M&A officer, effective Feb. 26, 2026. He brings more than 20 years of strategy, M&A and transformation experience from Danaher, Patheon and Banner Life Sciences.
Mr. Beauvalot will lead growth strategy, mergers and acquisitions, strategic partnerships and integrations, reporting to Jim Davis and joining the executive leadership team. He succeeds Dermot Shorten, who will retire in Q2 2026 after overseeing nearly 80 business combinations, including about 20 hospital outreach lab acquisitions.
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026 at 8:00 a.m. ET.
The fireside chat and Q&A will be webcast live on the company's investor relations site, with an archived replay available within 24 hours and accessible through March 25, 2026.
Quest Diagnostics (NYSE: DGX) reported fourth-quarter 2025 net revenues of $2.81 billion (up 7.1%) and full-year 2025 net revenues of $11.04 billion (up 11.8%). Reported diluted EPS was $2.18 for Q4 and $8.75 for full year; adjusted diluted EPS was $2.42 for Q4 and $9.85 for the year.
The company generated $1.89 billion of cash from operations in 2025, raised its quarterly dividend 7.5% to $0.86 per share, and provided 2026 guidance of $11.70–$11.82 billion in revenues and adjusted diluted EPS of $10.50–$10.70.
Quest Diagnostics (NYSE: DGX) announced a 7.5% increase in its quarterly cash dividend to $0.86 per share from $0.80, effective with the dividend payable on April 20, 2026 to shareholders of record on April 6, 2026.
The change raises the annual cash dividend to $3.44 per share and follows 15 consecutive years of dividend increases. The Board also authorized a $1 billion increase in the share repurchase program, added to approximately $0.4 billion available as of December 31, 2025.
Quest Diagnostics (NYSE: DGX) launched Quest Flow Cytometry MRD for Myeloma on Feb 2, 2026, an ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma.
The test reports sensitivity comparable to next-generation sequencing, five-day specimen stability versus three days for conventional flow, works without a pre-treatment baseline aspirate, and is promoted as lower cost to support broader access and clinical-trial monitoring.
Quest Diagnostics (NYSE: DGX) announced it was named to Fortune's 2026 World's Most Admired Companies list for the 12th consecutive year and ranked #2 in the "Health Care: Pharmacy and Other Services" industry category.
The recognition is based on nine corporate‑reputation attributes surveyed by Korn Ferry and Fortune, covering product quality, innovation, long‑term value, financial profile, responsibility, and people management. Quest highlighted its 55,000 colleagues and role delivering diagnostic insights from one of the largest de‑identified clinical lab databases, serving roughly one in three U.S. adults annually.
Sonora Quest Laboratories (NYSE:DGX) named Jennifer Erickson as Chief Executive Officer‑Elect, succeeding longtime CEO David Dexter, who will retire effective March 31, 2026. Dexter will work with Erickson starting Feb. 2, 2026 to complete a planned transition. Dexter led the company for more than 26 years, overseeing growth to a market‑share leadership position in Arizona and operations performing more than 100 million diagnostic tests per year. Erickson brings over 20 years of health‑care leadership and previously served as Sonora Quest CFO (1999–2004).
Quest Diagnostics (NYSE: DGX) will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026 before market open. The company will host a conference call at 8:30 a.m. Eastern Time the same day.
Dial-in details: 888-455-0391 (U.S./Canada) or 773-756-0467 (international) with passcode 7895081. The earnings release and live webcast will be posted at www.QuestDiagnostics.com/investor. Participants are advised to dial in ~10 minutes early.
A replay will be available online at the investor site and by phone at 866-388-5361 (domestic) or 203-369-0416 (international) from ~10:30 a.m. ET on February 10, 2026 until midnight ET on February 24, 2026. Investors are encouraged to review the company’s periodic SEC filings, including risk factors.
Quest Diagnostics (NYSE: DGX) announced that data using its Haystack MRD® circulating tumor DNA test will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium, held January 8-10, 2026 in San Francisco and online.
Two poster presentations on January 10, 2026 (12:00 PM–1:30 PM PST) will report: 1) reproducibility and clinical concordance of a tumor-informed MRD assay in resected colorectal cancer from the DYNAMIC trials (Abstract 26; lead author Jeanne Tie) and 2) use of ctDNA to monitor patients undergoing total neoadjuvant treatment for locally advanced rectal adenocarcinoma (Abstract 30; lead author Eric Christenson).